Drug therapy for sickle cell disease

Bibliography

• DEAN J, SCHECHTER A: Sickle cell anemia: molecular and cellular basis of therapeutic approaches. N Engl. I Med. (1978) 299:752–863.
   PubMed Web of Science ®Google Scholar
• CHARACHE S: Treatment of sickle cell anemia. Ann. Rev. Med. (1981) 32:195–206.
   PubMed Web of Science ®Google Scholar
• SERGEANT GR: Sickle Cell Disease. Oxford University Press, New York, USA (1985).
   Google Scholar
• CHARACHE S, LUBIN B, REID CB: Management and therapy of sickle cell disease. NIH Publication, Bathesda, USA (1984) 84:2117.
   Google Scholar
• RODGERS GP, DOVER GJ, UYESAKA N et al.: Augmentation by erythropoietin of the fetal hemoglobin response to hydroxyurea in sickle cell disease. N Engl. .1. Med. (1993) 328:73–80.
   Google Scholar
• VEITH R, GALANELLO R, PAPAYANNOPOULOU T et al.: Stimulation of F cell production in patients with sickle cell anemia treated with cytarabin or hydroxyurea. N Engl. J. Med. (1985) 313:1571–1575.
   PubMed Web of Science ®Google Scholar
• PLATT OS, ORKIN SH, DOVER Get al.: Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J. Clin. Invest. (1984) 74:652–656.
   Google Scholar
• FIBACH E, BURK LP, SCHECHTER AN et al.: Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or I3-thalassemia. Blood (1993) 81: 1630-1635.
   Google Scholar
• CHARACHE S, TERRIN MI, MOORE RD et al.: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New Engl. I Med. (1995) 322:1317–1322.
   Google Scholar
• SCHECHTER AN, NOGUCHI CT, RODGERS GP: Sickle cell disease. In: The molecular bash of blood diseases. Stamatoyannopoulos G, Niehius AW, Leder P, Majerus PW (Eds), Saunders Company, Philadelphia, USA (1987):187.
   Google Scholar
• HEBBEL RP: Beyond hemoglobin polymerization: the red blood cell membrane and sickle cell disease. Blood (1991) 77:214–237.
   PubMed Web of Science ®Google Scholar
• WAMBEBE C, KHAMOFU H, MOMOH JA et al.: Double-blind placebo, randomised cross-over clinical trial of NIPRISAN in patients with sickle cell disorders. Phytomedicine (2001) 8:252–261.
   PubMed Web of Science ®Google Scholar
• WAMBEBE CO, BAMBOYE EA, BARDU BO et al: Efficacy of Niprisan in the prophylactic management of patients with sickle cell disease. Can: Ther. Res (2001) 62:26–34.
   Google Scholar
• ••Described for the first time the efficacy levelas well as toxicity profiles of NIPRISAN in human subjects.
   Google Scholar
• BRUGNARA C, DE FRANCESCHI, ALPER SL: Inhibition of Ca2±-dependent K.+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J. Clin. Invest. (1993) 92:520–526.
   Google Scholar
• •Highlights procedures and the feasibility of using sustainable orally bioavailable agents for the treatment of SCD.
   Google Scholar
• BANK A, MARKOWITZ D, LERNER N: Gene transfer. A potential approach to gene therapy for sickle cell disease. Ann. New York Acad. Sri. (1989) 565:37–43.
   PubMed Web of Science ®Google Scholar
• PAWLIUK R, WESTERMAN KA, FABRY ME et al: Correction of sickle cell disease in transgenic mouse models by gene therapy. Science (2001) 294:2268–2271.
   Web of Science ®Google Scholar
• WALTERS MC, PATIENCE M, LEISENRING W et al.: Bone marrow transplantation for sickle cell disease N Engl. J. Med. (1996) 335:369–376.
   Google Scholar
• GIAMPALO A, MAVILIO F, SPOSI NM et al.: Heterocellular hereditary persistence of fetal hemoglobin (HPFH). Molecular mechanisms of abnormal 7-gene expression in association with I3-thalassemia and linkage relationship with the I3-globin gene cluster. Hum. Genet. (1984) 66:151–156.
   Google Scholar
• DRESLER WFC, STEIN R: Ueber den hydroxyharnstoff, justus liebigs. Ann. Chem. Pharmacol (1869) 150:242–252.
   Google Scholar
• ROSENTHAL FL, WISLICKI, KOLLER L: Ueber die beziehungen von schwesten blutgiften zu abbauprodukten des eiscisses. effi beitrag zum entstehungsmechanismus der pernziosen anamie. Klin. Wochstr. (1928) 7:972–977.
   Google Scholar
• PATEL D: Hydroxyurea- its value in 50 cases ofadvanced cancers. Indian J. Cancer (1973) 10:423–427.
   PubMedGoogle Scholar
• BLACOW NW: The Extra Pharmacopeia. Martindale (Ed.), The Pharmaceutical Press, London, UK (1972) 26:1205–1206.
   Google Scholar
• LORI F, MALYKH A, CARA A et al.: Hydroxyurea as inhibitor of human immunodeficiency virus Type 1 replication. Science (1994) 266:801–805.
   PubMed Web of Science ®Google Scholar
• BIRON F, LUCHT F, PEYRAMOND D et al.: Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-infected individuals. I Acquir. Immune H&c. Syndr. Hum. Retrovirol (1995) 10:36–40.
   PubMedGoogle Scholar
• WANG WC, WYNN LW, ROGERS ZR et al.: A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. Pediatr. (2001) 139:790–796.
   Web of Science ®Google Scholar
• COKIC VP, SMITH RD, BELESLIN-COKIC BB et al.: Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. Gifu. Invest. (2003) 111:231–239.
   PubMed Web of Science ®Google Scholar
• JIANG J, JORDAN SJ, BARR DP, GUNTHER MR et al.: In vivoproduction of nitric oxide in rats after administration of hydroxyurea MM. Pharmacol. (1997) 52:1081–1086.
   Web of Science ®Google Scholar
• GINDER GD, WHITTERS MJ, POHLMAN JK: Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate. Proc. Natl. Acad. Sci. (1984) 81:3954–3958.
   PubMed Web of Science ®Google Scholar
• BURNS LJ, GLAUBER JG, GINDER GD: Butyrate induces selective transcriptional activation of a hypomethylated embryonic globin gene in adult erythroid cells. Blood (1988) 72:1536–1542.
   PubMed Web of Science ®Google Scholar
• PERRINE SP, MILLER BA, GREENE ME et al.: Butryic acid analogues augment y-globin gene expression in neonatal erythroid progenitors. Biochem. Biophys. Res. Commun. (1987) 148:694–700.
   PubMed Web of Science ®Google Scholar
• ATWEH GE SUTTON M, NASSIF I et al.: Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood (1999) 93:1787–1789.
   Google Scholar
• SHER GD, GINDER GD, LITTLE J, YANG S, DOVER GJ, OLIVIERI NF: Extended therapy with intravenous arginine butyrate in patients with I3-hemoglobinopathies. N Engl. I Med. (1995) 32:1606–1610.
   Google Scholar
• IKUTA T, AUSENDA S, CAPPELLINI MD: Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc. Natl. Acad. Sci. (2001) 98:1847–1852.
   PubMed Web of Science ®Google Scholar
• ••Described for the first time, the mechanismunderlying the role of NO in the induction of Hb E
   Google Scholar
• KAABA SA, AL-HARBI SA: Reduced levels of CD2+ cells and T cell subsets in patients with sickle cell anaemia. Immunol. Lett. (1993) 37:77–81.
   PubMed Web of Science ®Google Scholar
• TAYLOR S, SHACKS S, QU Z: Effect of anti-IL-6 and anti-IL-10 monoclonal antibodies on the suppression of the normal T lymphocyte mitogenic response by steady state sickle cell disease sera. Immunol. Invest. (2001) 30:209–219.
   PubMed Web of Science ®Google Scholar
• IYAMU EW, TURNER EA, ASAKURA TA: In vitro effects of NIPRISAN (Nix-0699): a naturally occurring potent anti-sickfing agent. Br: J. Haematol. (2002) 118:337–343.
   Google Scholar
• •Highlights novel procedures to determine the efficacy of NIPRISAN in vitro.
   Google Scholar
• STOCKER JW, DE FRANCESCHI L, MCNAGHTON-SMITH GA et al.: ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and M vivoin SAD mice. Blood (2003) 101:2412–2418.
   PubMed Web of Science ®Google Scholar
• WINOGRAD E, SHERMAN IW: Characterization of a modified red cell membrane protein expressed on erythrocytes infected with the human malaria parasite Plasmodium fakiparum: possible role as a cytoadherent mediating protein. j. Cell Biol. (1989) 108:23–30.
   PubMed Web of Science ®Google Scholar
• GLAD WIN MT, SCHECHTER AN: Nitric oxide therapy in sickle cell disease. Semin. Hematol. (2001) 38:333–342.
   PubMed Web of Science ®Google Scholar